Company intelligence
Cizzle Bio, Inc.
Detect Early: Save Lives
About Cizzle Bio, Inc.
Cizzle Bio, Inc. is at the forefront of biotechnological innovation, dedicated to revolutionizing lung cancer detection through our pioneering CIZ1B biomarker blood test. Our mission is to improve early-stage lung cancer diagnosis, enhancing patient outcomes with non-invasive, highly accurate diagnostic solutions. In collaboration with Cizzle Biotechnology PLC, we utilize patented technologies to offer an effective alternative to traditional screening methods. With a focus on continuous innovation, strategic partnerships, and patient-centered care, we aim to make early cancer detection accessible and reliable for all.
Verified activity
Signals from Cizzle Bio, Inc.
2 published signals
Products & Services
Cizzle Bio, Inc. released the CIZ1B Biomarker Blood Test, designed to provide an additional biomarker-based tool for lung cancer assessments.
Reported by Cizzle Bio, Inc.
Research & Knowledge
Cizzle Bio, Inc. published new peer-reviewed research in The Journal of Applied Laboratory Medicine supporting the CIZ1B Biomarker Blood Test for Lung Cancer with 94% sensitivity and 97% negative predictive value in the early-stage cohort.
Reported by Cizzle Bio, Inc.